Special Issue "Advanced Research in Prostate Cancer"

A special issue of Biomedicines (ISSN 2227-9059).

Deadline for manuscript submissions: 15 October 2020.

Special Issue Editor

Dr. Ruth Vinall
Website
Guest Editor
California Northstate University College of Pharmacy, United States
Interests: prostate cancer; bladder cancer; natural products research; biomarkers; targeted therapy; miRNA; mechanisms of chemoresistance

Special Issue Information

Dear Colleagues,

Over the past few years, we have witnessed major advances in prostate cancer treatments. The trend, as for many cancer types, is moving toward the development and clinical usage of biomedicine-based approaches. For example, Sipuleucel-T, a prostate cancer vaccine which received FDA approval in 2010, is becoming more widely used in patients with metastatic disease. Pembrolizumab and Nivolumab, also immunotherapies, show much promise. Continued efforts in the area of natural products research indicate that natural bioactive products can help to reduce prostate cancer incidence and progression. Large-scale genomics projects have led to the ongoing development of several targeted therapies, and, importantly, the co-development of biomarkers will allow for the prediction and measurement of patient response. Lastly, implementation of innovative drug delivery technologies, for example, nanoparticles, is helping to improve drug response rates while minimizing off-target effects. This is an exciting time for prostate cancer research! This Special Edition of Biomedicines entitled ‘Advanced Research in Prostate Cancer’ will include reviews that describe major advances which have occurred in the treatment of prostate cancer over the past few years as well as original research articles that describe preclinical and/or translational studies which will support future advances.

On behalf of the Biomedicines journal, I invite you to submit a review article for this Special Edition. It would be an honor to work and co-publish with you. Articles should be focused on the development and usage, or potential usage, of biomedicines, including natural bioactive molecules, biologics, vaccines, and/or targeted therapies to treat prostate cancer. Articles which outline how genetic analyses can guide the development and use of these treatment options, or which describe innovative drug delivery strategies, are also welcomed.

Dr. Ruth Vinall
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • immunotherapy
  • natural bioactive products
  • targeted therapies
  • vaccines
  • biologics

Published Papers

This special issue is now open for submission.
Back to TopTop